Boehringer Ingelheim and partner launches stage II trials for NASH and obesity

In collaboration with Zealand Pharma, Boehringer Ingelheim is advancing to stage II trials with the drug candidate BI 456906 which is currently being tested as a treatment for type II diabetes. Now, the drug will prove its worth as a treatment for the fatty liver disease NASH and obesity.
Photo: Zealand Pharma / PR
Photo: Zealand Pharma / PR

Danish biotech company Zealand Pharma and its collaborative partner, German pharmaceutical company Boehringer Ingelheim, are initiating stage II trials with the drug candidate BI 456906.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading